Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vizimpro in EGFR-mutant NSCLC with brain metastasis
NCT04675008Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Dec 2020
- Primary completion
- Sep 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dacomitinib in non-small cell lung cancer (NSCLC), brain metastases, sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT04675008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04675008.